This article will provide a detailed overview of GFP antibodies from chicken, goat, mouse, and rabbit hosts, and how they can address different concerns in scientific research.

Ovarian cancer is the deadliest form of female gynecologic cancers causing more deaths than any other cancer of the female reproductive system.

Combining the exquisite specificity our minimally cross-reactive antibodies have always offered with the unique penetrative capabilities of the small VHH fragment format, JIR AffiniPure-VHH™ Secondary Antibodies enable high precision staining. Read our article to explore how they behave in mouse brain tissue.

AdipoGen Life Sciences (AdipoGen) is a research company developing proteins, biochemicals, antibodies and ELISA Kits. To promote the advancement of non-animal alternative approaches (3Rs), AdipoGen implemented the antibody phage display technology in-house to develop monoclonal antibodies without the use of animals.

The 21st of September is World Alzheimer’s Day. This is an event to raise awareness and challenge stigmas around Alzheimer’s disease (AD), which is the most common type of dementia today, affecting around 8 million people in Europe and 20 million worldwide. With an ever-growing elderly population, these numbers are only expected to increase in the coming decades, along with emotional and economic hardships for families as well as major healthcare efforts at high societal costs. 

Article originally published on Atlas Antibodies’website  and written by Dr. Laura Pozzi

Non-small cell lung cancers (NSCLCs) are epithelial lung cancers that differ from small cell lung cancers (SCLCs) by cells morphology and histology. Almost 85% of lung cancers are NSCLCs. 

Examples of NSCLCs include adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Still, several other types occur less frequently, and all varieties can occur in unusual histologic variants.  

Although NSCLCs are less aggressive and progress more slowly than SCLCs, they are often identified later, and by the time of diagnosis, they will have already spread beyond the lungs.  

Moreover, NSCLCs (in particular NSCLCs harboring KEAP1 mutations) are less sensitive and often resistant to chemotherapy, radiation, and immune checkpoint inhibitors immunotherapy compared with SCLCs.